Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.
作者信息
Porter Rebecca L, Matulonis Ursula A
机构信息
Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA.
出版信息
J Clin Oncol. 2021 Nov 20;39(33):3651-3655. doi: 10.1200/JCO.21.01886. Epub 2021 Sep 16.
Abstract
摘要
相似文献
1
Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.检查点阻断疗法：在卵巢癌中尚未达到“忍者”状态
J Clin Oncol. 2021 Nov 20;39(33):3651-3655. doi: 10.1200/JCO.21.01886. Epub 2021 Sep 16.
2
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.联合应用检查点激酶 1 抑制剂和鲁卡帕尼通过调节 BRCA 野生型上皮性卵巢癌细胞中 Rad51 表达增强疗效。
Cancer Res Treat. 2021 Jul;53(3):819-828. doi: 10.4143/crt.2020.1013. Epub 2020 Dec 16.
3
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.维利帕尼与拓扑替康用于BRCA阴性或BRCA状态未知的铂耐药或部分铂敏感复发性上皮性卵巢癌患者。
Cancer Treat Res Commun. 2018;14:7-12. doi: 10.1016/j.ctarc.2017.09.001. Epub 2017 Sep 27.
4
Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.阿特珠单抗和 LncRNA PVT1 阻断协同通过 JAK2/STAT3/PD-L1 通路抑制顺铂耐药卵巢癌细胞的进展。
Clin Immunol. 2021 Jun;227:108728. doi: 10.1016/j.clim.2021.108728. Epub 2021 Apr 17.
5
Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.表观遗传途径为卵巢癌治疗提供靶点。
Clin Breast Cancer. 2018 Jun;18(3):189-191. doi: 10.1016/j.clbc.2017.09.009. Epub 2017 Sep 19.
6
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.PARP1 抑制剂在 XRCC1 缺陷的散发性上皮性卵巢癌中具有合成致死作用。
Cancer Lett. 2020 Jan 28;469:124-133. doi: 10.1016/j.canlet.2019.10.035. Epub 2019 Oct 24.
7
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.现行策略在高级别浆液性上皮性卵巢癌的靶向治疗中的应用及 BRCA 突变状态的相关性。
J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
8
The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.长链非编码 RNA 对卵巢癌化疗反应的影响。
Gynecol Oncol. 2020 Mar;156(3):726-733. doi: 10.1016/j.ygyno.2019.12.020. Epub 2019 Dec 26.
9
Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.人类卵巢上皮性癌中的致癌和药物敏感的 RET 突变。
J Exp Clin Cancer Res. 2020 Mar 23;39(1):53. doi: 10.1186/s13046-020-01557-3.
10
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.奥拉帕利和 α 特异性 PI3K 抑制剂阿培利司治疗上皮性卵巢癌患者：一项剂量递增和剂量扩展的 1b 期试验。
Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.
引用本文的文献
1
Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies.挖掘免疫疗法在铂耐药卵巢癌中的潜力：原理、挑战及新策略
Cancer Drug Resist. 2024 Oct 15;7:39. doi: 10.20517/cdr.2024.67. eCollection 2024.
2
Siglec-9 tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer.Siglec-9 肿瘤相关巨噬细胞在高级别浆液性卵巢癌患者中划定了一个具有治疗脆弱性的免疫抑制亚群。
J Immunother Cancer. 2023 Sep;11(9). doi: 10.1136/jitc-2023-007099.
3
Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives.免疫疗法在铂耐药卵巢癌治疗中的应用现状
Onco Targets Ther. 2022 Aug 10;15:853-866. doi: 10.2147/OTT.S335936. eCollection 2022.
4
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype.卫星重复 RNA 在卵巢上皮性癌中的表达与肿瘤免疫抑制表型相关。
J Clin Invest. 2022 Aug 15;132(16). doi: 10.1172/JCI155931.
5
miR-600 promotes ovarian cancer cells stemness, proliferation and metastasis via targeting KLF9.miR-600 通过靶向 KLF9 促进卵巢癌细胞干性、增殖和转移。
J Ovarian Res. 2022 May 3;15(1):52. doi: 10.1186/s13048-022-00981-7.
6
Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.1809年至2022年及以后的卵巢癌研究视角
Diagnostics (Basel). 2022 Mar 24;12(4):791. doi: 10.3390/diagnostics12040791.
7
Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.奥拉帕尼与帕博利珠单抗和贝伐单抗三联组合疗法对一名患有ARID1A突变的卵巢透明细胞癌患者三线治疗的显著疗效：一例报告
Onco Targets Ther. 2022 Apr 2;15:323-328. doi: 10.2147/OTT.S362267. eCollection 2022.
8
Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram.经阴道超声检查在卵巢癌筛查中观察到盆腔积液的意义。
Diagnostics (Basel). 2022 Jan 7;12(1):144. doi: 10.3390/diagnostics12010144.
本文引用的文献
1
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).尼伏鲁单抗对比吉西他滨或多柔比星脂质体用于铂耐药卵巢癌患者：日本开放标签、随机试验（NINJA）。
J Clin Oncol. 2021 Nov 20;39(33):3671-3681. doi: 10.1200/JCO.21.00334. Epub 2021 Sep 2.
2
Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer.塑造卵巢癌肿瘤微环境中的免疫反应。
Front Immunol. 2021 Jun 23;12:692360. doi: 10.3389/fimmu.2021.692360. eCollection 2021.
3
Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.肠道微生物组和微生物衍生代谢物在癌症免疫检查点阻断免疫治疗中的作用。
Genome Med. 2021 Jun 23;13(1):107. doi: 10.1186/s13073-021-00923-w.
4
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.阿维鲁单抗单药或联合化疗对比单纯化疗用于铂耐药或铂难治性卵巢癌（JAVELIN Ovarian 200）：一项开放标签、三臂、随机、3期研究。
Lancet Oncol. 2021 Jul;22(7):1034-1046. doi: 10.1016/S1470-2045(21)00216-3. Epub 2021 Jun 15.
5
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).阿替利珠单抗、贝伐珠单抗联合化疗治疗新诊断的 III 期或 IV 期卵巢癌：安慰剂对照随机 III 期试验（IMagyn050/GOG 3015/ENGOT-OV39）。
J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23.
6
Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?卵巢癌中的免疫检查点抑制剂：我们能否弥合想象与现实之间的差距？
J Clin Oncol. 2021 Jun 10;39(17):1833-1838. doi: 10.1200/JCO.21.00571. Epub 2021 Apr 23.
7
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.帕博利珠单抗联合贝伐珠单抗和口服环磷酰胺节拍化疗治疗复发性卵巢癌的疗效和安全性：一项 2 期非随机临床试验。
JAMA Oncol. 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945.
8
Immune Therapy Opportunities in Ovarian Cancer.卵巢癌的免疫治疗机会。
Am Soc Clin Oncol Educ Book. 2020 May;40:1-13. doi: 10.1200/EDBK_280539.
9
Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance.液体活检在治疗反应和耐药性预测中的生物标志物研究进展。
Cancer Cell. 2020 Apr 13;37(4):485-495. doi: 10.1016/j.ccell.2020.03.012.
10
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.免疫基因组分析确定卵巢癌中联合 PARP 和 PD-1 抑制的反应。
Nat Commun. 2020 Mar 19;11(1):1459. doi: 10.1038/s41467-020-15315-8.
Zotero 插件